Keros Therapeutics, Inc.

NasdaqGM:KROS Stock Report

Market Cap: US$221.5m

Keros Therapeutics Management

Management criteria checks 3/4

Keros Therapeutics' CEO is Jas Seehra, appointed in Dec 2015, has a tenure of 10.42 years. total yearly compensation is $2.54M, comprised of 27.6% salary and 72.4% bonuses, including company stock and options. directly owns 1.88% of the company’s shares, worth $4.17M. The average tenure of the management team and the board of directors is 6.2 years and 5.4 years respectively.

Key information

Jas Seehra

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage27.56%
CEO tenure10.4yrs
CEO ownership1.9%
Management average tenure6.2yrs
Board average tenure5.4yrs

Recent management updates

Analysis Article • May 29

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Key Insights Keros Therapeutics to hold its Annual General Meeting on 4th of June Salary of US$699.0k is part of CEO...

Recent updates

Analysis Article • Nov 18

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Aug 21

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Summary Keros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential. KER-065 received FDA Orphan Drug designation for Duchenne Muscular Dystrophy, but efficacy and approval remain years away and unproven. Elritercept, now partnered with Takeda, offers milestone and royalty potential, but faces tough competition and uncertain commercial prospects. Given limited near-term catalysts and high risk, I maintain a Hold rating—Keros is interesting, but KROS stock lacks enough data for a bullish stance. Read the full article on Seeking Alpha
Analysis Article • May 29

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Key Insights Keros Therapeutics to hold its Annual General Meeting on 4th of June Salary of US$699.0k is part of CEO...
Analysis Article • May 14

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We did...
Analysis Article • May 09

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shares have had a really impressive month, gaining 44% after a shaky period...
Seeking Alpha • Mar 13

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Summary Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 13 quarters, but high short interest and low trading volume pose additional risks. Given the current situation, I recommend avoiding KROS, although risk-loving investors might find its low price and cash reserves appealing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Summary Keros Therapeutics, Inc.'s stock plummeted over 75% due to halting high-dose arms in its Phase 2 TROPOS trial for PAH, citing safety concerns. Despite the setback, Keros' partnership with Takeda Pharmaceutical Company for elritercept and its potential $900m annual revenue offers a safety net. The market reaction may be too harsh; past biotech clinical study setbacks have often been resolved, presenting a contrarian investment opportunity. Investors should wait for more data on cibotercept's safety issues before making definitive judgments. Read the full article on Seeking Alpha
Analysis Article • Nov 20

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 07

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jun 10

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS. The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029. Keros Therapeutics is also developing the use of KER-050 for the treatment of patients with myelofibrosis and data from the phase 2 study for this program is expected in Q4 2024. Read the full article on Seeking Alpha
Analysis Article • Apr 23

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Key Insights The projected fair value for Keros Therapeutics is US$94.52 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Sep 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jun 10

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 08

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 04

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Keros Therapeutics press release (NASDAQ:KROS): Q2 GAAP EPS of -$1.13 misses by $0.07. Cash and cash equivalents OF $215.62M
Analysis Article • Apr 29

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 05

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

CEO Compensation Analysis

How has Jas Seehra's remuneration changed compared to Keros Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$85m

Dec 31 2025US$3mUS$700k

US$87m

Sep 30 2025n/an/a

US$64m

Jun 30 2025n/an/a

US$19m

Mar 31 2025n/an/a

US$4m

Dec 31 2024US$6mUS$699k

-US$187m

Sep 30 2024n/an/a

-US$182m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$160m

Dec 31 2023US$9mUS$649k

-US$153m

Sep 30 2023n/an/a

-US$142m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$116m

Dec 31 2022US$6mUS$611k

-US$105m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$7mUS$557k

-US$59m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$53m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$10mUS$521k

-US$45m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$695kUS$485k

-US$14m

Compensation vs Market: Jas's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Jas's compensation has been consistent with company performance over the past year.

CEO

Jas Seehra (69 yo)

10.4yrs
Tenure
US$2,540,204
Compensation

Dr. Jasbir S. Seehra, also known as Jas, Ph D., is President of Keros Therapeutics, Inc. from August 18, 2025 and has been its Chief Executive Officer and Director since December 2015 and was its Chair of...

Leadership Team

NamePositionTenureCompensationOwnership
Jasbir Seehra
President10.4yrsUS$2.54m1.88%
$ 4.2m
Keith Regnante
Chief Financial Officer6.3yrsUS$1.11m0.049%
$ 109.5k
Esther Cho
Chief Legal Officer & Secretary6.1yrsUS$1.10m0.20%
$ 444.9k
Lorena Lerner
Chief Scientific Officerless than a yearno data0.16%
$ 348.3k
6.2yrs
Average Tenure
54yo
Average Age

Experienced Management: KROS's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jasbir Seehra
President10.4yrsUS$2.54m1.88%
$ 4.2m
Jean-Jacques Bienaime
Independent Chair of the Board1.9yrsUS$259.44k0.016%
$ 35.8k
Julius Knowles
Independent Director10.1yrsUS$239.04k0.0060%
$ 13.3k
Mary Gray
Independent Director5.4yrsUS$247.54k0.27%
$ 595.0k
Alpna Seth
Independent Director3yrsUS$238.54k0.17%
$ 373.0k
Nima Farzan
Independent Director6.2yrsUS$239.04k0.23%
$ 504.5k
Charles Newton
Independent Directorless than a yearno datano data
5.4yrs
Average Tenure
62yo
Average Age

Experienced Board: KROS's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 12:03
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Keros Therapeutics, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Corinne JohnsonGoldman Sachs
Andrew FeinH.C. Wainwright & Co.